ArticleJournal of hematology & oncology2012
The significance of low PU.1 expression in patients with acute promyelocytic leukemia.
Article in Journal of hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Super-enhancer-associated long noncoding RNA lnc-SPI1U mediates SPI1 feedback regulation by interacting with HNRNPH1 and HNRNPF.Oncogene · 2025Article
- The role of long noncoding RNAs in the diagnosis, prognosis and therapeutic biomarkers of acute myeloid leukemia.Annals of hematology · 2024Review
- Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.International journal of molecular sciences · 2022Article
- Comprehensive Analysis of Immune Implications and Prognostic Value of SPI1 in Gastric Cancer.Frontiers in oncology · 2022Article
- Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia.Nature communications · 2021Article
- Down-Regulation ofInternational journal of hematology-oncology and stem cell research · 2019Article
- The histone demethylase Jmjd3 regulates zebrafish myeloid development by promoting spi1 expression.Biochimica et biophysica acta. Gene regulatory mechanisms · 2018Article
- PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation.Journal of hematology & oncology · 2016Article
- PML-RAR alpha induces the downmodulation of HHEX: a key event responsible for the induction of an angiogenetic response.Journal of hematology & oncology · 2016Article
- Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells.Journal of leukocyte biology · 2015Article
- Zebrafish as a model for leukemia and other hematopoietic disorders.Journal of hematology & oncology · 2015Review
- Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression.FEBS open bio · 2015Article
- Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.Oncogene · 2014Article
- Article
- Structurally differentiated cis-elements that interact with PU.1 are functionally distinguishable in acute promyelocytic leukemia.Journal of hematology & oncology · 2013Article
- Preferential eradication of acute myelogenous leukemia stem cells by fenretinide.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- The differential expression pattern of the BMI-1, SALL4 and ABCA3 genes in myeloid leukemia.Cancer cell international · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the importance of the hematopoietic transcription factor PU.1 in acute myeloid leukemia (AML) has been demonstrated, the expression of PU.1 in acute promyelocytic leukemia (APL) patient samples awaits further investigation. The current study used APL patient samples to assess the expression pattern of PU.1 in the initiation and progression of APL.
findingsWe used real-time RT-PCR to compare PU.1 expression between de novo APL patient samples and normal blood specimens, and the results indicated that PU.1 expression was significantly lower in newly diagnosed APL patient samples as compared to normal hematopoietic cells. Further evidence showed a significant inverse correlation between the expression level of PML-RARα and that of PU.1. In addition, we analyzed the correlation between PML-RARα and PU.1 expression in a large population of AML patients retrieved from the expression profiles. The results showed that PU.1 expression was lower in patients with APL than other AML subtypes and there was also a trend towards increasing PU.1 expression from AML-M0 to AML-M5, with the exception of AML-M3 (APL). These observations suggested that PU.1 expression was reduced by PML-RARα in APL patients. Furthermore, we measured PU.1 expression in APL-initiating cells isolated from de novo APL patients by side population cell analysis and found that suppression of PU.1 expression occurred concurrently with PML-RARα expression, indicating the pivotal role of PU.1 in APL initiation.
conclusionOur findings provide evidence that low PU.1 expression in APL patients is required for disease initiation and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.